Thrivent Financial For Lutherans Allakos Inc. Transaction History

Thrivent Financial For Lutherans

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 16, 2022	SELL	$8.55 - $111.89 $34,559 - $452,259	-4,042 Closed	0 $0
Q2 2021 Aug 19, 2021	SELL	$85.37 - $114.1 $153,239 - $204,809	-1,795 Reduced 30.75%	4,042 $345,000
Q1 2021 May 17, 2021	SELL	$109.73 - $153.66 $82,736 - $115,859	-754 Reduced 11.44%	5,837 $670,000
Q4 2020 Feb 16, 2021	BUY	$79.58 - $152.45 $524,511 - $1 Million	6,591 New	6,591 $923,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.